<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04449484</url>
  </required_header>
  <id_info>
    <org_study_id>D6340C00002</org_study_id>
    <nct_id>NCT04449484</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of MEDI1341 in Subjects With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled study of multiple&#xD;
      ascending iv doses of MEDI341 in male and female subjects with Parkinson's Disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include up to 3 cohorts, with 12 subjects in each, for a total of up to 36&#xD;
      randomised subjects.&#xD;
&#xD;
      The study comprises a screening period of up to 49 days, an 8-week double-blind treatment&#xD;
      period, and a 13-week follow-up period. Each subject will receive three 60 minute iv&#xD;
      infusions of MEDI1341 or placebo during the 8-week treatment period, with 4 weeks between&#xD;
      infusions. The overall study duration (enrolment, treatment, and follow-up periods) will be&#xD;
      up to 28 weeks per subject.&#xD;
&#xD;
      A Dose Escalation Committee will review data from each cohort to allow progression to the&#xD;
      next higher dose cohort in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 4, 2020</start_date>
  <completion_date type="Actual">January 5, 2022</completion_date>
  <primary_completion_date type="Actual">January 5, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects are randomised to one of two groups within a cohort of 12 subjects (N=9 MEDI1341; N=3 Placebo)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>28 weeks</time_frame>
    <description>Incidence, Nature, Severity and Seriousness of adverse events from screening</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>21 weeks</time_frame>
    <description>Change from baseline in Blood Pressure measured in millimetres of Mercury</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral Body Temperature</measure>
    <time_frame>21 weeks</time_frame>
    <description>Change from baseline in body temperature measured in degrees Celcius</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Weight</measure>
    <time_frame>21 weeks</time_frame>
    <description>Change from baseline measured in Kilograms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Laboratory Tests</measure>
    <time_frame>21 weeks</time_frame>
    <description>Incidence from baseline in abnormal laboratory test results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiograms</measure>
    <time_frame>21 weeks</time_frame>
    <description>Change from baseline in ECG rythm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ophthalmic assessments</measure>
    <time_frame>21 weeks</time_frame>
    <description>Incidence from baseline in abnormal ocular findings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Suicidal Ideation</measure>
    <time_frame>21 weeks</time_frame>
    <description>Evaluation of presence or absence of suicidal ideation as measured by the Columbia Suicide Severity Rating Scale (C-SSRS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive impairment</measure>
    <time_frame>21 weeks</time_frame>
    <description>Change from baseline in the total score of the Montreal Cognitive assessment; a 30-point test (the higher the score, the better the cognition)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiograms</measure>
    <time_frame>21 weeks</time_frame>
    <description>Change from baseline in ECG heart rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiograms</measure>
    <time_frame>21 weeks</time_frame>
    <description>Change from baseline in ECG conduction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiograms</measure>
    <time_frame>21 weeks</time_frame>
    <description>Change from baseline in ECG PR interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiograms</measure>
    <time_frame>21 weeks</time_frame>
    <description>Change from baseline in ECG QRS interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiograms</measure>
    <time_frame>21 weeks</time_frame>
    <description>Change from baseline in ECG RR interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiograms</measure>
    <time_frame>21 weeks</time_frame>
    <description>Change from baseline in ECG QT interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiograms</measure>
    <time_frame>21 weeks</time_frame>
    <description>Change from baseline in ECG QTcF interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Suicidal Behaviour</measure>
    <time_frame>21 weeks</time_frame>
    <description>Evaluation of presence or absence of suicidal behaviour as measured by the Columbia Suicide Severity Rating Scale (C-SSRS)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>MEDI1341</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses given at 4 week intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 doses given at 4 week intervals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI1341</intervention_name>
    <description>Intravenous infusion over 60 minutes</description>
    <arm_group_label>MEDI1341</arm_group_label>
    <other_name>TAK-341</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion over 60 minutes</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Subjects must be aged 40 to 85 years, inclusive, on the day of randomization.&#xD;
&#xD;
          2. Meet criteria for a diagnosis of mild-to-moderate idiopathic PD according to the&#xD;
             United Kingdom Parkinson's Disease Society Brain Bank criteria (Hughes et al 1992)&#xD;
&#xD;
          3. PD should be stage 1 to 3 using the Hoehn and Yahr scale as modified (Goetz et al&#xD;
             2004).&#xD;
&#xD;
          4. Subjects receiving medications for PD should have been on a stable dosing regimen of&#xD;
             their medication(s) for ≥ 1 month before randomization, with no expectation of a need&#xD;
             to change the medications or dosing regimen for the duration of the study, barring&#xD;
             unforeseen circumstances. (For subjects who are not currently receiving medications to&#xD;
             treat PD, there should be no expectation of a need to initiate these for the duration&#xD;
             of the study).&#xD;
&#xD;
          5. Subjects must have a body weight of 45 to 120 kg, inclusive, and a body mass index of&#xD;
             18 to 34 kg/m2, inclusive at screening and at check-in for the first infusion.&#xD;
&#xD;
          6. Subjects may be male or female. Female subjects must of non-childbearing potential&#xD;
             (postmenopausal and/or surgically sterile.&#xD;
&#xD;
          7. Postmenopausal women must have had ≥ 12 months of spontaneous amenorrhea (with a&#xD;
             follicle-stimulating hormone [FSH] concentration ≥ 26 mIU/mL in women ≤ 60 years of&#xD;
             age; women &gt; 60 years of age do not require an FSH test) and must have had a negative&#xD;
             serum pregnancy test result at screening.&#xD;
&#xD;
             Surgically sterile women are defined as those who have had a hysterectomy, bilateral&#xD;
             ovariectomy (oophorectomy), salpingectomy, or bilateral tubal ligation. Women who are&#xD;
             surgically sterile must provide documentation of the procedure by an operative report,&#xD;
             ultrasound, or other verifiable medical documentation.&#xD;
&#xD;
          8. Men who are biologically capable of fathering children must agree and commit to use an&#xD;
             adequate form of double-barrier contraception for the duration of the treatment period&#xD;
             and for 5 half lives (100 days) after the last administration of study intervention. A&#xD;
             male subject is considered capable of fathering children even if his sexual partner is&#xD;
             sterile or using contraceptives.&#xD;
&#xD;
             Men who are biologically capable of fathering children must also agree to refrain from&#xD;
             sperm donation for the duration of the treatment period and for 5 half-lives or 90&#xD;
             days (whichever is longer) after the last administration of study intervention.&#xD;
&#xD;
          9. Subjects must, in the investigator's opinion, understand the nature of the study and&#xD;
             must provide signed and dated written informed consent before the conduct of any&#xD;
             study-related procedures.&#xD;
&#xD;
         10. Subjects must, in the opinion of the investigator, be able to participate in all&#xD;
             scheduled evaluations, likely to be compliant, and likely to complete all required&#xD;
             tests, including magnetic resonance imaging (MRI) brain scans and lumbar punctures&#xD;
             (LPs). (Note: The investigator should assess the physical and functional needs of the&#xD;
             subject at screening, as participation in the study may be contingent upon the&#xD;
             availability and willingness of a caregiver to attend with the subject at all study&#xD;
             visits.)&#xD;
&#xD;
         11. Subjects must be able to read, write, and speak fluently in English and/or Spanish.&#xD;
&#xD;
         12. Subjects must agree not to post any personal medical data related to the study or&#xD;
             information related to the study on any website or social media site (eg, Facebook,&#xD;
             Twitter, Instagram, etc) until the study has been completed.&#xD;
&#xD;
         13. Subjects must have a MoCA total score of ≥ 24.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. In the opinion of the investigator, a recent clinically significant illness (other&#xD;
             than PD), infection, medical/surgical procedure, or significant trauma within 30 days&#xD;
             prior to screening, or between screening and randomization, that is likely to&#xD;
             deteriorate, compromise the subject's safety or ability to complete the study, or&#xD;
             compromise the interpretation of the study results (Note: a history of coronavirus&#xD;
             disease 2019 [COVID 19] infection with unresolved medical sequelae would be considered&#xD;
             exclusionary.)&#xD;
&#xD;
          2. Presence of a serious or unstable clinically significant illness, including hepatic,&#xD;
             renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic or&#xD;
             autoimmune disease (eg, multiple sclerosis), hematologic or other major disease,&#xD;
             which, in the judgment of the investigator, is poorly controlled or otherwise likely&#xD;
             to deteriorate, compromise the subject's safety or ability to complete the study, or&#xD;
             compromise the interpretation of the study results&#xD;
&#xD;
          3. Significant neurological disease affecting the CNS (other than PD) that, in the&#xD;
             opinion of the investigator, may affect motor function or the ability to complete the&#xD;
             study, including but not limited to progressive supranuclear palsy, multiple system&#xD;
             atrophy (MSA; including MSA-P and MSA-C or other MSA terminology: striatonigral&#xD;
             degeneration, olivopontocerebellar atrophy or autonomic failure), postencephalitic&#xD;
             parkinsonism, metabolic diseases with parkinsonian signs and symptoms (eg, Wilson&#xD;
             disease, manganese exposure) or other secondary forms of Parkinsonism, and ischemic or&#xD;
             traumatic brain injury (including multiple episodes of head trauma, or head trauma&#xD;
             resulting in protracted loss of consciousness within the 5 years prior to screening or&#xD;
             between screening and randomization)&#xD;
&#xD;
          4. Brain MRI scan that shows clinically significant evidence of malignant, ischemic,&#xD;
             demyelinating, structural, or degenerative brain disease or has findings that&#xD;
             compromise the safety of LP&#xD;
&#xD;
          5. Has undergone surgery for the treatment of PD (eg, pallidotomy, deep brain&#xD;
             stimulation, fetal tissue transplantation) or has undergone any other brain surgery at&#xD;
             any time, even for non-PD conditions&#xD;
&#xD;
          6. History of epilepsy or seizures, except febrile childhood seizures&#xD;
&#xD;
          7. History of transient ischemic attack or stroke or any unexplained loss of&#xD;
             consciousness within 1 year prior to screening or between screening and randomization&#xD;
&#xD;
          8. Presence of any psychiatric disorder according to the criteria of the Diagnostic and&#xD;
             Statistical Manual of Mental Disorders, 5th Edition (DSM-V; APA 2013) or symptom if,&#xD;
             in the judgment of the investigator, the psychiatric disorder or symptom is likely to&#xD;
             confound interpretation of the study results, affect motor function assessment, or&#xD;
             affect the subject's ability to complete the study&#xD;
&#xD;
          9. A diagnosis of intellectual disability (intellectual developmental disorder) or mental&#xD;
             retardation, or significant inherited cognitive impairment&#xD;
&#xD;
         10. Suicidality, represented by answering &quot;yes&quot; to Question 4 or Question 5 on the C SSRS,&#xD;
             indicating active suicidal ideation with any intent to act, during the subject's&#xD;
             lifetime, as assessed at screening, or between screening and randomization&#xD;
&#xD;
         11. Suicidal behavior such that a determination of &quot;yes&quot; is made on the Suicidal Behavior&#xD;
             section of the C SSRS for &quot;Actual Attempt,&quot; &quot;Interrupted Attempt,&quot; &quot;Aborted Attempt,&quot;&#xD;
             or &quot;Preparatory Acts or Behavior,&quot; during the subject's lifetime, as assessed at&#xD;
             screening, or between screening and randomization&#xD;
&#xD;
         12. History of alcohol or drug abuse or dependence (except nicotine dependence), as&#xD;
             defined by the DSM-V, within 2 years prior to screening or between screening and&#xD;
             randomization&#xD;
&#xD;
         13. Within 1 year prior to screening, any of the following: myocardial infarction;&#xD;
             hospitalization for congestive heart failure; hospitalization for, or symptoms of&#xD;
             unstable angina; unexplained syncope&#xD;
&#xD;
         14. Moderate or severe congestive heart failure, or known ejection fraction &lt; 40%&#xD;
&#xD;
         15. Known significant structural heart disease (eg, significant valvular disease,&#xD;
             hypertrophic cardiomyopathy) that is considered likely to lead to a deterioration of&#xD;
             cardiac function over the course of the study&#xD;
&#xD;
         16. History of cancer within 5 years prior to screening or between screening and&#xD;
             randomization, with the exception of non-metastatic basal and/or squamous cell&#xD;
             carcinoma of the skin&#xD;
&#xD;
         17. History of allergy/hypersensitivity to immunizations or immunoglobulins&#xD;
&#xD;
         18. Any condition that, in the opinion of the investigator or medical monitor, makes the&#xD;
             subject unsuitable for the study&#xD;
&#xD;
         19. Requires treatment with another monoclonal antibody&#xD;
&#xD;
         20. Use of any investigational medicine, device, or biologic within 3 months or 5&#xD;
             half-lives of that intervention (whichever is longer) prior to screening&#xD;
&#xD;
         21. Previous allogeneic bone marrow or stem cell transplant&#xD;
&#xD;
         22. Use of typical or atypical antipsychotic medication, or other medication with dopamine&#xD;
             antagonist properties (eg, metoclopramide, domperidone), within 6 months prior to&#xD;
             randomization&#xD;
&#xD;
         23. Use of immunosuppressive medication within 6 months prior to randomization. (Note:&#xD;
             Inhaled and topical corticosteroids are permitted. Low-dose systemic corticosteroids&#xD;
             [&lt; 10 mg per day prednisone or equivalent], for autoimmune disease that is considered&#xD;
             to be quiescent, in remission, or otherwise well controlled are permitted). Other&#xD;
             immunosuppressive drugs and biologics are contraindicated.&#xD;
&#xD;
         24. Received non-leukocyte depleted whole blood transfusion within 6 months prior to&#xD;
             screening&#xD;
&#xD;
         25. Received any commercially available vaccine within 30 days prior to randomization.&#xD;
             (Note: for COVID-19 vaccines authorized by the FDA for emergency use, this time frame&#xD;
             applies from last vaccination or booster dose, whichever is required to consider&#xD;
             vaccination complete in line with applicable guidance.)&#xD;
&#xD;
         26. Participation in another study investigating:&#xD;
&#xD;
               1. Active or passive immunization against α synuclein for PD, at any time prior to&#xD;
                  screening, or&#xD;
&#xD;
               2. Immunoglobulin G therapy within 6 months before screening&#xD;
&#xD;
         27. Any clinically significant abnormality as determined by investigator at screening or&#xD;
             between screening and randomization in physical examination, vital signs, ECG, or&#xD;
             clinical laboratory test results that may compromise the subject's safety or ability&#xD;
             to complete the study or compromise the interpretation of the study results&#xD;
&#xD;
         28. Presence of any of the following MRI contraindications: pacemaker; cardiac&#xD;
             defibrillator; spinal cord or vagus nerve stimulator; aneurysm clip; artificial heart&#xD;
             valve; recent (within one year) coronary or carotid stent; ear implant; CSF shunt;&#xD;
             other implanted medical device (eg, insulin pump); metal fragments or foreign objects&#xD;
             in the eyes, skin, or body; claustrophobia that would contraindicate a brain MRI scan&#xD;
&#xD;
         29. Brain MRI findings (or historical radiologic reports, if available) that show evidence&#xD;
             of clinically significant structural brain disease which, in the opinion of the&#xD;
             investigator, contraindicates performance of LP&#xD;
&#xD;
         30. Any spinal abnormality or other aspects (eg, tattoos) or other clinical findings&#xD;
             (papilledema seen with ophthalmoscopy) that may complicate or contraindicate LP, as&#xD;
             judged by the investigator&#xD;
&#xD;
         31. Ophthalmic abnormalities. The following are considered exclusionary:&#xD;
&#xD;
               1. Congenital or acquired ophthalmic conditions (primary or secondary) that are&#xD;
                  considered poorly controlled within the last 12 months prior to screening, with&#xD;
                  or without treatment, or otherwise expected to lead to significant deterioration&#xD;
                  in visual acuity in the next 6 months after randomization&#xD;
&#xD;
               2. Specific ophthalmic conditions:&#xD;
&#xD;
             i. Current or past history of inflammation affecting the uveal tract or sclera ii.&#xD;
             Diabetic retinopathy iii. Neovascular or exudative (wet) form of age-related macular&#xD;
             degeneration iv. Active central serous retinopathy (central serous chorioretinopathy)&#xD;
             v. Subjects with active autoimmune disease vi. Subjects taking immunosuppressive drugs&#xD;
             (other than low doses of systemic steroids [&lt; 10 mg per day of prednisone equivalent],&#xD;
             for autoimmune disease that is considered to be inactive, in remission, or otherwise&#xD;
             well-controlled). Other immunosuppressive drugs are contraindicated.&#xD;
&#xD;
             vii. Mature cataracts (Grade ≥ 4 per the Lens Opacities Classification System III) or&#xD;
             lower grade cataracts that are otherwise considered by the examining ophthalmologist&#xD;
             to prevent adequate examination of the uveal tract or posterior ocular segment. (Note:&#xD;
             Previous cataract surgery or an age-related cataract with age-appropriate lens&#xD;
             opacification and no other important identified secondary causes [eg, diabetes,&#xD;
             corticosteroids, vitamin deficiencies, trauma, radiation, or systemic fluid and&#xD;
             electrolyte disturbances] is not necessarily exclusionary.)&#xD;
&#xD;
         32. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) concentrations &gt;1.5&#xD;
             × the upper limit of normal (ULN) at screening, or between screening and baseline&#xD;
&#xD;
         33. Estimated creatinine clearance &lt; 50 mL/min or creatinine &gt; 1.5 × ULN at screening&#xD;
&#xD;
         34. Clinically significant vital sign abnormalities at screening or on Day 1, defined as&#xD;
             (a) systolic blood pressure ≥ 160 mmHg, (b) diastolic blood pressure ≥ 90 mmHg (blood&#xD;
             pressure assessed at rest; may be repeated up to 3 times), or (c) pulse rate &lt; 45 or &gt;&#xD;
             100 beats per minute (at rest)&#xD;
&#xD;
         35. Clinically significant abnormality in ECG rhythm, conduction or morphology at&#xD;
             screening or between screening and randomization, including but not limited to:&#xD;
&#xD;
               -  Clinically significant PR (PQ) interval prolongation (PR &gt; 220 msec)&#xD;
&#xD;
               -  Intermittent second or third degree atrioventricular (AV) block (AV block II&#xD;
                  Mobitz Type I, Wenckebach, while asleep or in deep rest is not exclusionary)&#xD;
&#xD;
               -  Bundle branch block or intraventricular conduction delay with QRS interval&#xD;
                  duration ≥ 120 msec&#xD;
&#xD;
               -  A Fridericia's corrected QT (QTcF) interval measurement &gt; 470 msec, or a&#xD;
                  shortened QTcF &lt; 340 msec, at screening or between screening and randomization;&#xD;
                  or a family history of long or short QT syndrome&#xD;
&#xD;
         36. Positive serologic findings for human immunodeficiency virus (HIV) antibodies,&#xD;
             hepatitis B surface antigen, or hepatitis C virus antibodies, with relevant&#xD;
             confirmatory testing conducted, where applicable, in accordance with Centers for&#xD;
             Disease Control and Prevention guidance for HIV and viral hepatitis&#xD;
&#xD;
         37. Current blood clotting or bleeding disorder, including clinically significant abnormal&#xD;
             findings in laboratory tests of coagulation&#xD;
&#xD;
         38. Poor venous access, such that IV drug delivery or PK/safety blood sampling would be&#xD;
             difficult&#xD;
&#xD;
         39. Donation of blood or plasma within 2 months prior to screening and until 2 months&#xD;
             after the final follow-up visit&#xD;
&#xD;
         40. A positive serum pregnancy test result at screening or prior to randomization&#xD;
&#xD;
         41. Urine drug screen positive for a drug of abuse (except for permitted, prescribed&#xD;
             opiates and /or benzodiazepines). A urine drug screen positive for cannabinoids is&#xD;
             exclusionary unless there is a documented legitimate medical reason for the subject's&#xD;
             cannabinoid use (eg, chronic pain) or the investigator and medical monitor agree that&#xD;
             the subject can abstain from use for the duration of the study.&#xD;
&#xD;
         42. Current employment by the sponsor (AstraZeneca) or by a contract research organization&#xD;
             or clinical study site participating in this study, or a first-degree relative of an&#xD;
             AstraZeneca employee or of an employee at a participating contract research&#xD;
             organization or clinical study site&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beth E. Safirstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Clinical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2022</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>June 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2020</study_first_posted>
  <last_update_submitted>June 2, 2022</last_update_submitted>
  <last_update_submitted_qc>June 2, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymised individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_description>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de- identified individual patient-level data in an approved sponsor tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04449484
org study id: D6340C00002
nct id: NCT04449484
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
This is a multicenter, randomized, double-blind, placebo-controlled study of multiple
      ascending iv doses of MEDI341 in male and female subjects with Parkinson's Disease.
The study will include up to 3 cohorts, with 12 subjects in each, for a total of up to 36
      randomised subjects.

      The study comprises a screening period of up to 49 days, an 8-week double-blind treatment
      period, and a 13-week follow-up period. Each subject will receive three 60 minute iv
      infusions of MEDI1341 or placebo during the 8-week treatment period, with 4 weeks between
      infusions. The overall study duration (enrolment, treatment, and follow-up periods) will be
      up to 28 weeks per subject.

      A Dose Escalation Committee will review data from each cohort to allow progression to the
      next higher dose cohort in the study.
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: Subjects are randomised to one of two groups within a cohort of 12 subjects (N=9 MEDI1341; N=3 Placebo)
primary purpose: Treatment
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Adverse Events
time frame: 28 weeks
description: Incidence, Nature, Severity and Seriousness of adverse events from screening
measure: Vital Signs
time frame: 21 weeks
description: Change from baseline in Blood Pressure measured in millimetres of Mercury
measure: Oral Body Temperature
time frame: 21 weeks
description: Change from baseline in body temperature measured in degrees Celcius
measure: Body Weight
time frame: 21 weeks
description: Change from baseline measured in Kilograms
measure: Safety Laboratory Tests
time frame: 21 weeks
description: Incidence from baseline in abnormal laboratory test results
measure: Electrocardiograms
time frame: 21 weeks
description: Change from baseline in ECG rythm
measure: Ophthalmic assessments
time frame: 21 weeks
description: Incidence from baseline in abnormal ocular findings
measure: Suicidal Ideation
time frame: 21 weeks
description: Evaluation of presence or absence of suicidal ideation as measured by the Columbia Suicide Severity Rating Scale (C-SSRS)
measure: Cognitive impairment
time frame: 21 weeks
description: Change from baseline in the total score of the Montreal Cognitive assessment; a 30-point test (the higher the score, the better the cognition)
measure: Electrocardiograms
time frame: 21 weeks
description: Change from baseline in ECG heart rate
measure: Electrocardiograms
time frame: 21 weeks
description: Change from baseline in ECG conduction
measure: Electrocardiograms
time frame: 21 weeks
description: Change from baseline in ECG PR interval
measure: Electrocardiograms
time frame: 21 weeks
description: Change from baseline in ECG QRS interval
measure: Electrocardiograms
time frame: 21 weeks
description: Change from baseline in ECG RR interval
measure: Electrocardiograms
time frame: 21 weeks
description: Change from baseline in ECG QT interval
measure: Electrocardiograms
time frame: 21 weeks
description: Change from baseline in ECG QTcF interval
measure: Suicidal Behaviour
time frame: 21 weeks
description: Evaluation of presence or absence of suicidal behaviour as measured by the Columbia Suicide Severity Rating Scale (C-SSRS)
arm group label: MEDI1341
arm group type: Experimental
description: 3 doses given at 4 week intervals
arm group label: Placebo
arm group type: Placebo Comparator
description: 3 doses given at 4 week intervals
intervention type: Drug
intervention name: MEDI1341
description: Intravenous infusion over 60 minutes
arm group label: MEDI1341
other name: TAK-341
intervention type: Other
intervention name: Placebo
description: Intravenous infusion over 60 minutes
arm group label: Placebo
criteria: 
gender: All
minimum age: 40 Years
maximum age: 85 Years
healthy volunteers: No
last name: Beth E. Safirstein, MD
role: Principal Investigator
affiliation: MD Clinical
facility: 
facility: 
facility: 
facility: 
facility: 
country: United States
responsible party type: Sponsor
mesh term: Parkinson Disease
sharing ipd: Yes
ipd description: Qualified researchers can request access to anonymised individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
ipd time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
ipd access criteria: When a request has been approved AstraZeneca will provide access to the de- identified individual patient-level data in an approved sponsor tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
ipd url: https://astrazenecagroup-dt.pharmacm.com/DT/Home